6505--Generic Lenalidomide for the Minneapolis VA

Where this opportunity stands

Every notice posted under solicitation 36C26326Q0214 in this department, oldest first.

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

• Note the winner and the end of the period of performance for the recompete.
• Follow the agency to see the next notice for this work.

Who won similar work

13 award notices on SAM.gov in the last 24 months. Matched by: Same office (NETWORK CONTRACT OFFICE 23 (36C263)), same product/service code (PSC) 6505 and NAICS 325412.

Single-winner award sizes (13): middle half $669K to $1.4M, median $1.1M; range $87K to $3.6M.

Value counts new single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling (same contract, or the same office, day and amount); that ceiling is not one company's win, so it is not added in. Contract modifications are not new awards and are not added in either. Revenue next to a ticker is the company's revenue over the latest 12 months in its SEC filings.

• Oct 1, 2026BRACCO DIAGNOSTICS INC.$363K6505--Rh-82 Rhubidium Generator - Iowa City VANo listed company matched (Materiality N/A)
• May 14, 2026HOT SHOTS NM LLC$87KNon-PET RadiopharmaceuticalsNo listed company matched (Materiality N/A)
• Jan 2, 2026EXELAN PHARMACEUTICALS INC$1.4M6505--Generic Lenalidomide for the Black Hills VANo listed company matched (Materiality N/A)
• Dec 12, 2025HOT SHOTS NM LLC$742K6505--Awarded - SOLE SOURCE Radiopharmaceutical F-18 FDG Tracer Doses to Hot Shots NM LLCNo listed company matched (Materiality N/A)
• Dec 11, 2025HOT SHOTS NM LLC$742K6505--AWARDED -F-18 FDG (Fludeoxyglucose) Radioactive Tracer Doses, IDIQ Contract, Base plus Three Ordering Periods of one year each.No listed company matched (Materiality N/A)
• Nov 28, 2025EXELAN PHARMACEUTICALS INC$1.2M6505--Lenalidomide Generic CapsulesNo listed company matched (Materiality N/A)
• Nov 20, 2025EXELAN PHARMACEUTICALS INC$3.6M6505--Lenalidomide CapsulesNo listed company matched (Materiality N/A)
• Nov 18, 2025EXELAN PHARMACEUTICALS INC$1.1M6505--Generic Lenalidomide Medication-Supply-STCNo listed company matched (Materiality N/A)
• Oct 2, 2025PETNET SOLUTIONS, INC.$2.9M6505--Minneapolis VA Health Care System Radiopharmaceuticals Contract Award NoticeNo listed company matched (Materiality N/A)
• Oct 1, 2025CARDINAL HEALTH 414, LLC$3.3MRadioisotopes - Fargo & SFMateriality: <0.01% of $CAH revenue (Low)Calculated as Award Amount divided by the company's trailing twelve-month revenue (SEC 10-Q). For this company the latest 10-K year is used. Here: $3.3M award ÷ $254.2B revenue, fiscal year ending Jun 30, 2026 (SEC 10-K). SEC

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 6 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.